Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.
Apple and Masimo’s legal battle over the Apple Watch’s Blood Oxygen sensing feature continues this week as both firms meet in ...
It's been more than a year since Apple Watch Ultra 2 launched, and we've had the wearable that's only gotten better on our ...
The retrial came less than a week after Time Magazine named Masimo’s W1 Medical Watch one of the best inventions of 2024, ...
Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...
In its first earnings report since the departure of longtime CEO Joe Kiani, Masimo said Tuesday it is focused on reducing spending to drive long-term growth. The company continues to evaluate ...
Unrecognized Contract Revenues: $1.65 billion as of the end of Q3. Masimo Corp (NASDAQ:MASI) reported healthcare revenues of $343 million for the third quarter, representing a 12% growth compared ...
Piper Sandler raised the firm’s price target on Masimo (MASI) to $180 from $165 and keeps an Overweight rating on the shares. The firm notes the company announced Q3 revenue of $505M finished ...
Q3 2024 Earnings Call Transcript November 5, 2024 Masimo Corporation beats earnings expectations. Reported EPS is $0.98, expectations were $0.84. Operator: Ladies and gentlemen, good afternoon, and ...
Exhaled breath contains chemical clues to what's going on inside the body, including diseases like lung cancer.